ArticleFrontiers in medicine2026
Toremifene-induced bilateral macular crystalline deposits with cystic cavitation: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tamoxifen-induced retinopathy is well recognized and frequently reported in clinical practice. By contrast, ocular adverse events associated with the structurally similar agent toremifene remain rarely described. We present a case of bilateral visual impairment in a patient receiving long-term oral toremifene citrate for secondary prevention after breast cancer surgery. Ophthalmic evaluation showed yellowish-white crystalline deposits within the macular retinal layers in both eyes. Optical coherence tomography (OCT) revealed cystic vacuolization in the bilateral foveal regions, with features closely resembling tamoxifen-induced retinopathy. A clinical diagnosis of toremifene-associated retinopathy was established. This case may provide reference for clinicians when judging the appropriate timing of toremifene withdrawal. Should drug cessation be considered, a joint assessment by ophthalmologists and oncologists should be performed to balance the risks of tumor progression and ocular damage before reaching a clinical decision. In addition, this case supplements available evidence regarding toremifene-related ocular toxicity and raises clinical awareness of this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.